Trial Profile
An Open-Label Long Term Effectiveness and Safety Study of Oxymorphone Extended Release Tablets in Patients With Cancer or Neuropathic Pain.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Dec 2009
Price :
$35
*
At a glance
- Drugs Oxymorphone (Primary)
- Indications Cancer pain; Neuropathic pain
- Focus Adverse reactions
- Sponsors Endo Pharmaceuticals
- 06 Jun 2009 New trial record